Portal Hypertension clinical trials

Explore recruiting portal hypertension clinical trials.

Recruiting portal hypertension studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Portal Hypertension trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Effects of Metformin on hepatic venous pressure gradient in patients with cirrhosis and portal hypertension – A randomized placebo-controlled study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

Netherlands, France, Norway, Hungary, Italy, Lithuania +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis

Spain, Austria, Netherlands, Germany, Denmark, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

APIS Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective, randomized, double-blind, placebo-controlled, crossover phase IIa study on the safety of EdoXaban in PortosinusOidal vaScUlar disorder (EXPOSURE)

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of one dose (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in decompensated cirrhosis after their first decompensation event, who are stabilized CTP 5-7

Spain, Romania, Germany, France, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Portal Hypertension trials by city

Portal Hypertension in Toronto Portal Hypertension in Vancouver Portal Hypertension in Montreal Portal Hypertension in Calgary Portal Hypertension in Edmonton Portal Hypertension in Ottawa Portal Hypertension in Winnipeg Portal Hypertension in Quebec City Portal Hypertension in Hamilton Portal Hypertension in Kitchener Portal Hypertension in London Portal Hypertension in Halifax Portal Hypertension in New York Portal Hypertension in Los Angeles Portal Hypertension in Chicago Portal Hypertension in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease